News

Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company`s net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

Zydus Lifesciences has launched REVAHALE� (Revefenacin), India`s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). REVAHALE is the first and only LAMA available in India that combines once-daily dosing with nebulized administration, offering a new treatment option for COPD patients who require nebulised therapy. Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALE addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment. COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. While inhaled bronchodilator therapies have transformed disease management, many patients continue to experience difficulties using handheld inhalers, cognitive limitations, severe breathlessness, or an inability to generate sufficient inspiratory effort for effective drug delivery. REVAHALE has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow. The therapy is compatible with standard jet nebulisers, providing flexibility and ease of use for patients and caregivers.

Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease. Sickle Cell Disease is a significant public health concern in India, especially among tribal populations where prevalence is higher. According to National Health Mission estimates, nearly 20 million people live with the condition, and roughly 50,000 children are born with sickle cell anaemia annually. While treatments like hydroxyurea and blood transfusions exist, their limited accessibility, inconsistent effectiveness, and associated risks remain significant challenges.

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield� Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.